Raymond James Financial Services Advisors Inc. purchased a new position in shares of Enhabit, Inc. (NYSE:EHAB – Get Rating) during the third quarter, HoldingsChannel.com reports. The fund purchased 41,702 shares of the company’s stock, valued at approximately $585,000.
A number of other large investors have also made changes to their positions in EHAB. CI Investments Inc. acquired a new position in shares of Enhabit during the second quarter worth $27,000. Millennium Management LLC purchased a new stake in shares of Enhabit during the second quarter valued at $230,000. Louisiana State Employees Retirement System purchased a new stake in shares of Enhabit during the third quarter valued at $333,000. OLD Mission Capital LLC purchased a new stake in shares of Enhabit during the second quarter valued at $379,000. Finally, Northern Trust Corp purchased a new stake in shares of Enhabit during the second quarter valued at $494,000. 95.55% of the stock is owned by institutional investors and hedge funds.
Enhabit Price Performance
NYSE:EHAB opened at $14.61 on Wednesday. The firm’s fifty day moving average is $13.52 and its two-hundred day moving average is $14.42. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.63. Enhabit, Inc. has a one year low of $11.65 and a one year high of $25.25.
Insider Transactions at Enhabit
In related news, Director Jeffrey Bolton purchased 2,000 shares of Enhabit stock in a transaction that occurred on Wednesday, November 9th. The stock was purchased at an average price of $12.75 per share, for a total transaction of $25,500.00. Following the transaction, the director now directly owns 14,597 shares in the company, valued at $186,111.75. The acquisition was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Jeffrey Bolton purchased 2,000 shares of Enhabit stock in a transaction that occurred on Wednesday, November 9th. The stock was purchased at an average price of $12.75 per share, for a total transaction of $25,500.00. Following the transaction, the director now directly owns 14,597 shares in the company, valued at $186,111.75. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gregory S. Rush purchased 8,300 shares of Enhabit stock in a transaction that occurred on Monday, November 7th. The shares were bought at an average price of $12.69 per share, with a total value of $105,327.00. Following the transaction, the director now owns 16,597 shares in the company, valued at $210,615.93. The disclosure for this purchase can be found here. Insiders have bought a total of 13,000 shares of company stock valued at $164,903 in the last ninety days.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on EHAB shares. Credit Suisse Group dropped their price objective on shares of Enhabit from $19.00 to $15.00 and set a “neutral” rating on the stock in a report on Friday, November 4th. Oppenheimer started coverage on shares of Enhabit in a report on Thursday, October 13th. They set a “market perform” rating on the stock. Stifel Nicolaus started coverage on shares of Enhabit in a report on Monday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. UBS Group started coverage on shares of Enhabit in a report on Thursday, December 8th. They issued a “sell” rating and a $12.00 price target on the stock. Finally, CJS Securities started coverage on shares of Enhabit in a report on Tuesday, December 13th. They issued a “market perform” rating and a $18.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $16.43.
About Enhabit
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Articles
- Get a free copy of the StockNews.com research report on Enhabit (EHAB)
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
Want to see what other hedge funds are holding EHAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enhabit, Inc. (NYSE:EHAB – Get Rating).
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.